Have a feature idea you'd love to see implemented?
Let us know!
TRDA Entrada Therapeutics Inc
Price (delayed)
$18.05
Market cap
$675.43M
P/E Ratio
10.81
Dividend/share
N/A
EPS
$1.67
Enterprise value
$654.75M
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody,
Highlights
TRDA's quick ratio has surged by 195% year-on-year and by 15% since the previous quarter
The equity has soared by 71% YoY
Entrada Therapeutics's revenue has soared by 147% YoY but it has decreased by 10% from the previous quarter
The gross profit has surged by 147% year-on-year but it has declined by 10% since the previous quarter
TRDA's net income is down by 47% QoQ
TRDA's EPS is down by 46% from the previous quarter
Key stats
What are the main financial stats of TRDA
Market
Valuations
Earnings
Shares outstanding
37.42M
Market cap
$675.43M
Enterprise value
$654.75M
Price to earnings (P/E)
10.81
Price to book (P/B)
1.59
Price to sales (P/S)
3.41
EV/EBIT
8.57
EV/EBITDA
8.19
EV/Sales
3.04
Revenue
$215.23M
EBIT
$76.42M
EBITDA
$79.94M
Free cash flow
-$17.46M
Per share
Balance sheet
Liquidity
EPS
$1.67
Free cash flow per share
-$0.43
Book value per share
$11.36
Revenue per share
$5.3
TBVPS
$13.65
Total assets
$554.59M
Total liabilities
$132.14M
Debt
$61.31M
Equity
$422.45M
Working capital
$394.73M
Debt to equity
0.15
Current ratio
6.59
Quick ratio
6.46
Net debt/EBITDA
-0.26
Margins
Efficiency
Dividend
EBITDA margin
37.1%
Gross margin
100%
Net margin
25.5%
Operating margin
26.8%
Return on assets
10.4%
Return on equity
16.1%
Return on invested capital
20.8%
Return on capital employed
15.8%
Return on sales
35.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRDA stock price
How has the Entrada Therapeutics stock price performed over time
Intraday
0.67%
1 week
-5.2%
1 month
4.21%
1 year
8.28%
YTD
19.62%
QTD
12.95%
Financial performance
How have Entrada Therapeutics's revenue and profit performed over time
Revenue
$215.23M
Gross profit
$215.23M
Operating income
$57.78M
Net income
$54.95M
Gross margin
100%
Net margin
25.5%
Entrada Therapeutics's operating margin has surged by 169% YoY but it has decreased by 31% QoQ
Entrada Therapeutics's revenue has soared by 147% YoY but it has decreased by 10% from the previous quarter
The gross profit has surged by 147% year-on-year but it has declined by 10% since the previous quarter
TRDA's net income is down by 47% QoQ
Growth
What is Entrada Therapeutics's growth rate over time
Valuation
What is Entrada Therapeutics stock price valuation
P/E
10.81
P/B
1.59
P/S
3.41
EV/EBIT
8.57
EV/EBITDA
8.19
EV/Sales
3.04
TRDA's EPS is down by 46% from the previous quarter
The equity has soared by 71% YoY
Entrada Therapeutics's revenue has soared by 147% YoY but it has decreased by 10% from the previous quarter
The stock's P/S is 14% more than its last 4 quarters average of 3.0
Efficiency
How efficient is Entrada Therapeutics business performance
Entrada Therapeutics's return on equity has shrunk by 54% QoQ
Entrada Therapeutics's return on assets has decreased by 49% QoQ
The ROIC has declined by 37% since the previous quarter
TRDA's ROS is down by 23% from the previous quarter
Dividends
What is TRDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRDA.
Financial health
How did Entrada Therapeutics financials performed over time
TRDA's quick ratio has surged by 195% year-on-year and by 15% since the previous quarter
Entrada Therapeutics's current ratio has surged by 184% YoY and by 16% QoQ
TRDA's debt is 85% less than its equity
The equity has soared by 71% YoY
Entrada Therapeutics's debt to equity has decreased by 46% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.